48 results on '"Rivolta F."'
Search Results
2. Health-related Quality of Life in Hymenoptera Venom Allergy: Validation of the Italian version of the Vespid Allergy Quality of Life Questionnaire (VQLQ-i)
- Author
-
Mauro, M., primary, Bignardi, D., additional, Baiardini, I., additional, Bonadonna, P., additional, Braschi, M.C., additional, Emiliani, F., additional, Guerra, L., additional, Liberati, S., additional, Olivieri, F., additional, Pravettoni, V., additional, Preziosi, D., additional, Ridolo, E., additional, Rivolta, F., additional, Martini, M., additional, and Bilò, M.B., additional
- Published
- 2024
- Full Text
- View/download PDF
3. The role of skin tests with polyethylene glycol and polysorbate 80 in the vaccination campaign for COVID-19: results from an Italian multicenter survey
- Author
-
Montera, M C, Giordano, A, Asperti, C, Aruanno, Arianna, Barzaghi, C E, Bignardi, D, Borrelli, P, Bommarito, L, Busa, Mattia Fernando, Calafiore, P, Carusi, V, Cinquini, M, Cortellini, G, Cocchi, Riccardo, D'Auria, F, De Caro, F, Demonte, A, Di Leo, E, Di Lizia, M, Di Rienzo, A, Fumagalli, Francesca, Kihlgren, P, Lodi Rizzini, F, Macchia, D, Manzotti, G, Marra, A M, Mileto, P, Mietta, S, Montagni, M, Nettis, E, Nucera, Eleonora, Peveri, S, Pivetta, D, Pirisi, M, Ramirez, G A, Rivolta, F, Rizzi, Angela, Savoia, Andrea Alessio, Pedicini, A, Scarpa, A, Zisa, G, Yacoub, M-R, Aruanno, A, Busa, M, Cocchi, R, Fumagalli, F, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Savoia, A, Montera, M C, Giordano, A, Asperti, C, Aruanno, Arianna, Barzaghi, C E, Bignardi, D, Borrelli, P, Bommarito, L, Busa, Mattia Fernando, Calafiore, P, Carusi, V, Cinquini, M, Cortellini, G, Cocchi, Riccardo, D'Auria, F, De Caro, F, Demonte, A, Di Leo, E, Di Lizia, M, Di Rienzo, A, Fumagalli, Francesca, Kihlgren, P, Lodi Rizzini, F, Macchia, D, Manzotti, G, Marra, A M, Mileto, P, Mietta, S, Montagni, M, Nettis, E, Nucera, Eleonora, Peveri, S, Pivetta, D, Pirisi, M, Ramirez, G A, Rivolta, F, Rizzi, Angela, Savoia, Andrea Alessio, Pedicini, A, Scarpa, A, Zisa, G, Yacoub, M-R, Aruanno, A, Busa, M, Cocchi, R, Fumagalli, F, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), and Savoia, A
- Abstract
Background. International guidelines suggested skin tests with Polyethylene-glycol (PEG) and polysorbate 80 (PS-80), to investigate a possible hypersensitivity to these excipients either to identify subjects at risk of developing allergic reactions to Covid-19 vaccines, or in patients with suspected IgE mediated hypersensitivity reactions (HR) to the Covid-19 vaccine. The main purpose of this study was to investigate the prevalence of PEG and PS sensitization in patients with a clinical history of HR to drugs containing PEG/PS and in patients with a suspected Covid-19 vaccine immediate HR. Methods. This was a multicenter retrospective study conducted by allergists belonging to 20 Italian medical centers. Skin testing was performed in 531 patients with either a clinical history of suspected hypersensitivity reaction (HR) to drugs containing PEG and/or PS-80 (group 1:362 patient) or a suspected HR to Covid-19 vaccines (group 2: 169 patient), as suggested by the AAIITO/SIAAIC guidelines for the "management of patients at risk of allergic reactions to Covid-19 vaccines" [1]. Results. 10/362 (0.02%) had positive skin test to one or both excipients in group 1, 12/169 (7.1%) in group 2 (p less than 0.01). In group 2 HRs to Covid-19 vaccines were immediate in 10/12 of cases and anaphylaxis occurred in 4/12 of patients. Conclusions. The positivity of skin test with PEG and or PS before vaccination is extremely rare and mostly replaceable by an accurate clinical history. Sensitization to PEG and PS has to be investigated in patients with a previous immediate HR to a Covid-19 vaccine, in particular in patients with anaphylaxis.
- Published
- 2023
4. Acetylsalicylic acid (ASA) desensitization in an allergic pregnant woman post-vascular scaffolds implantation
- Author
-
Rivolta, F., primary, Chiei Gallo, A., additional, Sangalli, A., additional, and Pravettoni, V., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
- Author
-
Scichilone, Nicola, Antonelli Incalzi, Raffaele, Blasi, Francesco, Schino, Pietro, Cuttitta, Giuseppina, Zullo, Alessandro, Ori, Alessandra, Canonica, Giorgio Walter, Schino P, Cuttitta G, Foschino MP, Prediletto R, Tranfa C, Zappa MC, Patriciello P, Labate L, Mariotta S, Nava S, Vatrella A, Mastroberardino M, Sarzani R, Iuliano A, Maggi L, Zedda A, Pesci A, Sera G, Nicolini A, Salvatore Walter DD, Forte S, Mario DD, Rivolta F, Ferliga M, Raco AF, Luigi DR, Cabibbo G, Maselli R, Gulotta C, Nardini S, Guffanti EE, Castellani W, Triolo L, Passalacqua G, Beghè B, Salvatore LC, Faccini E, Atzeni E, Tazza R, Giamesio P., Scichilone N., Antonelli Incalzi R., Blasi F., Schino P., Cuttitta G., Zullo A., Ori A., Canonica G., Foschino M.P., Prediletto R., Tranfa C.M.E., Zappa M.C., Patriciello P., Labate L., Mariotta S., Nava S., Vatrella A., Mastroberardino M., Sarzani R., Iuliano A., Maggi L., Zedda A., Pesci A., Sera G., Nicolini A., Salvatore Walter D.D., Forte S., Mario D.D., Rivolta F., Ferliga M., Raco A.F., Luigi D.R., Cabibbo G., Maselli R., Gulotta C., Nardini S., Guffanti E.E., Castellani W., Triolo L., Passalacqua G., Beghe B., Salvatore L.C., Faccini E., Atzeni E., Tazza R., Giamesio P., Scichilone, N, Antonelli Incalzi, R, Blasi, F, Schino, P, Cuttitta, G, Zullo, A, Ori, A, Canonica, G, Foschino, M, Prediletto, R, Tranfa, C, Zappa, M, Patriciello, P, Labate, L, Mariotta, S, Nava, S, Vatrella, A, Mastroberardino, M, Sarzani, R, Iuliano, A, Maggi, L, Zedda, A, Pesci, A, Sera, G, Nicolini, A, Salvatore Walter, D, Forte, S, Mario, D, Rivolta, F, Ferliga, M, Raco, A, Luigi, D, Cabibbo, G, Maselli, R, Gulotta, C, Nardini, S, Guffanti, E, Castellani, W, Triolo, L, Passalacqua, G, Beghe, B, Salvatore, L, Faccini, E, Atzeni, E, Tazza, R, Giamesio, P, Scichilone, Nicola, Antonelli Incalzi, Raffaele, Blasi, Francesco, Schino, Pietro, Cuttitta, Giuseppina, Zullo, Alessandro, Ori, Alessandra, Canonica, Giorgio, Walter, Foschino, Mp, Zappa, Mc, Salvatore Walter, Dd, Mario, Dd, Raco, Af, Luigi, Dr, Guffanti, Ee, Beghè, B, Salvatore, Lc, and Giamesio, P.
- Subjects
Male ,Chronic bronchitis ,Time Factors ,Health Status ,Anxiety ,Hospital Anxiety and Depression Scale ,Severity of Illness Index ,Health Statu ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Surveys and Questionnaires ,Forced Expiratory Volume ,Clinical phenotype ,Medicine ,Surveys and Questionnaire ,Respiratory function ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Lung ,Depression (differential diagnoses) ,COPD ,Depression ,Middle Aged ,Circadian Rhythm ,Phenotype ,Italy ,Female ,medicine.symptom ,24-hour symptoms, Clinical phenotype, Real-world, Respiratory function ,Research Article ,Human ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Chronic Obstructive ,Time Factor ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Pulmonary Disease ,03 medical and health sciences ,Internal medicine ,Humans ,Asthma ,24-hour symptoms ,Real-world ,Aged ,Sleep ,Quality of Life ,lcsh:RC705-779 ,business.industry ,Correction ,lcsh:Diseases of the respiratory system ,medicine.disease ,24-hour symptom ,Prospective Studie ,030228 respiratory system ,business - Abstract
Background Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline early-morning, day-time and nocturnal symptoms (gathered via the Night-time, Morning and Day-time Symptoms of COPD questionnaire), HR-QoL (via the St. George’s Respiratory Questionnaire), anxiety and depression levels (via the Hospital Anxiety and Depression Scale), quality of sleep (via COPD and Asthma Sleep Impact Scale), physical activity (via the International Physical Activity Questionnaire) as well as lung function were recorded. Results 606 COPD subjects (age 71.4 ± 8.2 years, male 75.1%) were studied. 57.9, 35.5 5.3 and 1.3% of the sample belonged to the CB, EM, MCA and EM + CB phenotypes respectively. The vast majority of subjects reported early-morning and day-time symptoms (79.5 and 79.2% in the CB and 75.8 and 77.7% in the EM groups); the proportion suffering from night-time symptoms was higher in the CB than in the EM group (53.6% vs. 39.5%, p = 0.0016). In both CB and EM, indiscriminately, the presence of symptoms during the 24-h day was associated with poorer HR-QoL, worse quality of sleep and higher levels of anxiety/depression. Conclusions The findings highlight the primary classificatory role of nocturnal symptoms in COPD. Trial registration Trial registration number: NCT03105999, date of registration: 10th April 2017.
- Published
- 2019
6. Features of ragweed allergy: symptoms and drug consumption related to airborne ragweed pollen concentrations in Northern Italy
- Author
-
Bonini, M, Monti, GS, Ceriotti, V, Re, EE, Bramè, B, Bottero, P, Tosi, A, Vaghi, A, Martelli, A, Traina, GM, Rivolta, L, Rivolta, F, Ortolani, CM, Bonini, M, Monti, G, Ceriotti, V, Re, E, Bramè, B, Bottero, P, Tosi, A, Vaghi, A, Martelli, A, Traina, G, Rivolta, L, Rivolta, F, and Ortolani, C
- Subjects
correlation ,immunoterapy ,epidemiology - Published
- 2020
7. Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study
- Author
-
Scichilone, N, Antonelli Incalzi, R, Blasi, F, Schino, P, Cuttitta, G, Zullo, A, Ori, A, Canonica, G, Foschino, M, Prediletto, R, Tranfa, C, Zappa, M, Patriciello, P, Labate, L, Mariotta, S, Nava, S, Vatrella, A, Mastroberardino, M, Sarzani, R, Iuliano, A, Maggi, L, Zedda, A, Pesci, A, Sera, G, Nicolini, A, Salvatore Walter, D, Forte, S, Mario, D, Rivolta, F, Ferliga, M, Raco, A, Luigi, D, Cabibbo, G, Maselli, R, Gulotta, C, Nardini, S, Guffanti, E, Castellani, W, Triolo, L, Passalacqua, G, Beghe, B, Salvatore, L, Faccini, E, Atzeni, E, Tazza, R, Giamesio, P, Scichilone N., Antonelli Incalzi R., Blasi F., Schino P., Cuttitta G., Zullo A., Ori A., Canonica G., Foschino M. P., Prediletto R., Tranfa C. M. E., Zappa M. C., Patriciello P., Labate L., Mariotta S., Nava S., Vatrella A., Mastroberardino M., Sarzani R., Iuliano A., Maggi L., Zedda A., Pesci A., Sera G., Nicolini A., Salvatore Walter D. D., Forte S., Mario D. D., Rivolta F., Ferliga M., Raco A. F., Luigi D. R., Cabibbo G., Maselli R., Gulotta C., Nardini S., Guffanti E. E., Castellani W., Triolo L., Passalacqua G., Beghe B., Salvatore L. C., Faccini E., Atzeni E., Tazza R., Giamesio P., Scichilone, N, Antonelli Incalzi, R, Blasi, F, Schino, P, Cuttitta, G, Zullo, A, Ori, A, Canonica, G, Foschino, M, Prediletto, R, Tranfa, C, Zappa, M, Patriciello, P, Labate, L, Mariotta, S, Nava, S, Vatrella, A, Mastroberardino, M, Sarzani, R, Iuliano, A, Maggi, L, Zedda, A, Pesci, A, Sera, G, Nicolini, A, Salvatore Walter, D, Forte, S, Mario, D, Rivolta, F, Ferliga, M, Raco, A, Luigi, D, Cabibbo, G, Maselli, R, Gulotta, C, Nardini, S, Guffanti, E, Castellani, W, Triolo, L, Passalacqua, G, Beghe, B, Salvatore, L, Faccini, E, Atzeni, E, Tazza, R, Giamesio, P, Scichilone N., Antonelli Incalzi R., Blasi F., Schino P., Cuttitta G., Zullo A., Ori A., Canonica G., Foschino M. P., Prediletto R., Tranfa C. M. E., Zappa M. C., Patriciello P., Labate L., Mariotta S., Nava S., Vatrella A., Mastroberardino M., Sarzani R., Iuliano A., Maggi L., Zedda A., Pesci A., Sera G., Nicolini A., Salvatore Walter D. D., Forte S., Mario D. D., Rivolta F., Ferliga M., Raco A. F., Luigi D. R., Cabibbo G., Maselli R., Gulotta C., Nardini S., Guffanti E. E., Castellani W., Triolo L., Passalacqua G., Beghe B., Salvatore L. C., Faccini E., Atzeni E., Tazza R., and Giamesio P.
- Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods: The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline early-morning, day-time and nocturnal symptoms (gathered via the Night-time, Morning and Day-time Symptoms of COPD questionnaire), HR-QoL (via the St. George's Respiratory Questionnaire), anxiety and depression levels (via the Hospital Anxiety and Depression Scale), quality of sleep (via COPD and Asthma Sleep Impact Scale), physical activity (via the International Physical Activity Questionnaire) as well as lung function were recorded. Results: 606 COPD subjects (age 71.4 ± 8.2 years, male 75.1%) were studied. 57.9, 35.5 5.3 and 1.3% of the sample belonged to the CB, EM, MCA and EM + CB phenotypes respectively. The vast majority of subjects reported early-morning and day-time symptoms (79.5 and 79.2% in the CB and 75.8 and 77.7% in the EM groups); the proportion suffering from night-time symptoms was higher in the CB than in the EM group (53.6% vs. 39.5%, p = 0.0016). In both CB and EM, indiscriminately, the presence of symptoms during the 24-h day was associated with poorer HR-QoL, worse quality of sleep and higher levels of anxiety/depression. Conclusions: The findings highlight the primary classificatory role of nocturnal symptoms in COPD. Trial registration: Trial registration number: NCT03105999, date of registration: 10th April 2017.
- Published
- 2019
8. Systemic allergic reactions induced by labile plant-food allergens: Seeking potential cofactors. A multicenter study
- Author
-
Asero, R., Ariano, R., Aruanno, A., Barzaghi, C., Borrelli, P., Busa, M., Celi, G., Cinquini, M., Cortellini, G., D'Auria, F., De Carli, M., Di Paolo, C., Garzi, G., Lodi Rizzini, F., Magnani, M., Manzotti, G., Marra, A., Miceli Sopo, Stefano, Murzilli, F., Nucera, Eleonora, Pinter, E., Pravettoni, V., Rivolta, F., Rizzi, Angela, Saporiti, N., Scala, E., Villalta, D., Yacoub, M. -R., Zisa, G., Miceli Sopo S. (ORCID:0000-0002-8175-6146), Nucera E. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Asero, R., Ariano, R., Aruanno, A., Barzaghi, C., Borrelli, P., Busa, M., Celi, G., Cinquini, M., Cortellini, G., D'Auria, F., De Carli, M., Di Paolo, C., Garzi, G., Lodi Rizzini, F., Magnani, M., Manzotti, G., Marra, A., Miceli Sopo, Stefano, Murzilli, F., Nucera, Eleonora, Pinter, E., Pravettoni, V., Rivolta, F., Rizzi, Angela, Saporiti, N., Scala, E., Villalta, D., Yacoub, M. -R., Zisa, G., Miceli Sopo S. (ORCID:0000-0002-8175-6146), Nucera E. (ORCID:0000-0002-0565-7680), and Rizzi A. (ORCID:0000-0002-6795-746X)
- Abstract
Background: Heat-and-pepsin-sensitive plant food allergens (PR-10 and profilin) sometimes cause systemic reaction. Objective: To detect the risk factors for systemic reactions induced by labile food allergens. Methods: A retrospective multicenter study was performed on patients with a documented history of systemic allergic reaction to labile plant food allergens and on age-matched controls with a history of oral allergy syndrome (OAS) induced by the same foods. Offending foods, their amount, and state (solid or liquid), and potential cofactors (nonsteroidal anti-inflammatory drugs, protonic pump inhibitors, exercise, alcohol, and fasting) were considered. Results: We studied 89 patients and 81 controls. Sensitization to PR-10 or profilin, IgE to Bet v 1 and/or Bet v 2, and foods causing OAS were similar in the two groups. Twenty patients experienced >1 systemic allergic reaction. Tree nuts, Rosaceae, Apiaceae, and soymilk were the main offending foods. Seventeen (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in controls; P <.025). The ingestion of the offending food in liquid form (soymilk) was frequent among patients (15%) but unusual among controls (2%; P <.025). Soy milk-induced systemic reactions were independent of PPI treatment. Fasting and excess of allergen, but not NSAID and exercise, were other relevant cofactors for systemic reactions. Systemic reactions occurred without any identifiable cofactor in 39 (44%) cases. Conclusion: PR-10- and profilin-induced systemic reactions are facilitated by PPI, ingestion of large amounts of unprocessed foods, and fasting. Soybean beverages represent a risk for PR-10 hypersensitive patients and should be avoided.
- Published
- 2021
9. New allergens in fruits and vegetables
- Author
-
Pastorello, E. A., Incorvaia, C., Pravettoni, V., Farioli, L., Conti, A., Viganò, G., Rivolta, F., Ispano, M., Rotondo, F., and Ortolani, C.
- Published
- 1998
10. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy
- Author
-
Giampaolo A, Abbonizio F, Puopolo M, Arcieri R, Mannucci PM, Hassan HJ, Accorsi A, Ettorre PC, Schiavoni M, Palareti G, Rodorigo G, Valdré L, Amaddii G, Billio A, Notarangelo L, Iannacaro P, Muleo P, Biasioli C, Rossi V, Alatri A, Testa S, Vincenzi D, Scapoli G, Morfini M, Molinari AC, Lapecorella M, Mariani G, Baudo F, Caimi MT, Federici AB, Gringeri A, Santagostino E, Marietta M, Coppola A, Perricone C, Schiavulli M, Miraglia E, Rocino A, Zanon E, Gagliano F, Mancuso G, Siragusa S, Rivolta F, Tagliaferri A, Gamba G, Iorio A, Oliovecchio E, Dragani A, Arbasi MC, Albertini P, Mancino A, Lombardo VT, Latella C, D'Incà M, Landolfi Raffaele, Biondo Francesca, Mazzucconi MG, Santoro Cristina, Mameli AL, Piseddu G, Schinco PC, Messina M, Rossetti G, Barillari G, Feola G, Franchini M, Gandini G, Castaman G, Rodeghiero F, Italian Association of Haemophilia Centres, DI MINNO, GIOVANNI, Giampaolo, A, Abbonizio, F, Puopolo, M, Arcieri, R, Mannucci, Pm, Hassan, Hj, Accorsi, A, Ettorre, Pc, Schiavoni, M, Palareti, G, Rodorigo, G, Valdré, L, Amaddii, G, Billio, A, Notarangelo, L, Iannacaro, P, Muleo, P, Biasioli, C, Rossi, V, Alatri, A, Testa, S, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Lapecorella, M, Mariani, G, Baudo, F, Caimi, Mt, Federici, Ab, Gringeri, A, Santagostino, E, Marietta, M, Coppola, A, DI MINNO, Giovanni, Perricone, C, Schiavulli, M, Miraglia, E, Rocino, A, Zanon, E, Gagliano, F, Mancuso, G, Siragusa, S, Rivolta, F, Tagliaferri, A, Gamba, G, Iorio, A, Oliovecchio, E, Dragani, A, Arbasi, Mc, Albertini, P, Mancino, A, Lombardo, Vt, Latella, C, D'Incà, M, Landolfi, Raffaele, Biondo, Francesca, Mazzucconi, Mg, Santoro, Cristina, Mameli, Al, Piseddu, G, Schinco, Pc, Messina, M, Rossetti, G, Barillari, G, Feola, G, Franchini, M, Gandini, G, Castaman, G, Rodeghiero, F, and Italian Association of Haemophilia, Centres
- Subjects
Clotting factor ,Male ,Pediatrics ,medicine.medical_specialty ,Factor VIII ,business.industry ,Haemophilia A ,Hematology ,Disease ,medicine.disease ,Haemophilia ,Hemophilia A ,Hemophilia B ,Factor IX ,On demand treatment ,Coagulation ,Italy ,Surveys and Questionnaires ,medicine ,Humans ,Female ,National registry ,business ,Coagulation Disorder - Abstract
Dear Sir, Treatment of haemophilia is costly, and it must be carefully monitored by physicians and health authorities, so as to improve the planning of the supply of factor concentrates obtained from the fractionation of human plasma or by recombinant technology. Therapy with coagulation factors can be used either prophylactically to prevent bleeding, which entails multiple weekly infusions, or on-demand, through infusion of the amount of factors determined by the severity of the disease and patient’s weight, to stop ongoing bleeding. According to a recent study, factor VIII (FVIII) consumption among persons with haemophilia A (HA) has increased in countries with high-income economies (Stonebraker et al., 2010). In Italy, haemophiliacs and other persons with congenital coagulation disorders are monitored by the National Registry of Congenital Coagulopathies (NRCC) established at the Istituto Superi=
- Published
- 2011
11. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy
- Author
-
Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A, Contino L, Accorsi A, Ettorre C, Scaraggi FA, Rodorigo G, Valdrè L, Targhetta R, Tagariello G, Radossi P, Muleo G, Biasioli C, Morfini M, Molinari AC, Mariani G, Carloni MT, Cantori I, Mannucci PM, Coppola A, Schiavulli M, Zanon E, Tagliaferri A, Rivolta F, Marchesini E, Marcucci M, Dragani A, D'Inca M, Luciani M, Mazzucconi MG, Santoro C, Schinco P, Rossetti G, Barillari G, Gandini G, Castaman G., DI MINNO, GIOVANNI, Rocca, A, Pizzinelli, S, Oliovecchio, E, Santagostino, E, Rocino, A, Iorio, A, Contino, L, Accorsi, A, Ettorre, C, Scaraggi, Fa, Rodorigo, G, Valdrè, L, Targhetta, R, Tagariello, G, Radossi, P, Muleo, G, Biasioli, C, Morfini, M, Molinari, Ac, Mariani, G, Carloni, Mt, Cantori, I, Mannucci, Pm, DI MINNO, Giovanni, Coppola, A, Schiavulli, M, Zanon, E, Tagliaferri, A, Rivolta, F, Marchesini, E, Marcucci, M, Dragani, A, D'Inca, M, Luciani, M, Mazzucconi, Mg, Santoro, C, Schinco, P, Rossetti, G, Barillari, G, Gandini, G, and Castaman, G.
- Abstract
Background: The in vivo recovery of recombinant factor IX (rFIX) is reported to be lower than that of plasma-derived products, with potential clinical implications for dosing. In clinical practice, a conversion (augmentation) factor is suggested to calculate the necessary doses of rFIX. The aim of this study was to assess the range of values for the conversion factor in usual clinical practice in Italy. Materials and methods: The study was questionnaire-based and proposed to all Italian Haemophilia centres treating patients with haemophilia B. Age, weight, dosage used in the last effective infusion, treatment regimen (prophylaxis versus on-demand), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) status, and years of previous therapy with rFIX were recorded for patients with severe haemophilia B treated with rFIX. Mean, standard deviation, median and range were calculated for demographic and treatment data for the overall population and for subgroups. The conversion factor for the theoretical dosage of 40 IU/Kg was calculated. Results: Among 207 patients with severe haemophilia B being followed in 24 centres, 138 (66.7%) were being treated with rFIX. The sample of 207 patients represents 83.1% of the population of Italian patients with severe haemophilia B. The age range of the studied patients was 0-72 years (mean, 24 years) and the weight range was 3-108 kg (mean, 60 kg). Nineteen patients (14.4%) were positive for HIV and 51 (42.9%) were positive for HCV. The mean dosage of rFIX was 44 IU/Kg, with no significant difference between those receiving the product as prophylaxis or on-demand. A reduction in dosage was observed with increasing age (0.23 IU/kg/year). The mean value for the conversion factor was 1.10 ± 0.36 (median 1.00, range 0.51- 2.08), when estimated for the whole population. No effect of HIV and HCV status was found on the dose prescribed. No evident correlation was found with the underlying genetic mutation. Discussion: We found that dosing of rFIX in clinical practice is very close to that of plasmaderived FIX concentrates. As a consequence, dosing in the non-surgical setting should be started using the same criteria as those for plasma-derived FIX and treatment effectiveness verified on a clinical basis rather than relying on in vivo recovery assessments.
- Published
- 2011
12. Adherence issues related to sublingual immunotherapy as perceived by allergists
- Author
-
Scurati, S., Frati, F., Passalacqua, G., Puccinelli, P., Hilaire, C., Incorvaia, C., D Avino, G., Comi, R., Lo Schiavo, M., Pezzuto, F., Montera, C., Pio, A., Teresa Ielpo, M., Cellini, F., Vicentini, L., Pecorari, R., Aresu, T., Capra, L., Benedictis, E., Bombi, C., Zauli, D., Vanzi, A., Alberto Paltrinieri, C., Bondioli, A., Paletta, I., Ventura, D., Mei, F., Paolini, F., Colangelo, C., Cavallucci, E., Cucinelli, F., Tinari, R., Ermini, G., Beltrami, V., Novembre, E., Begliomini, C., Marchese, E., Solito, E., Ammannati, V., Molino, G., Galli, E., Baldassini, M., Di Michele, L., Calvani, M., Gidaro, M., Venuti, A., Li Bianchi, E., Benassi, F., Pocobelli, D., Zangari, P., Rocco, M. G., Lo Vecchio, A., Pingitore, G., Grimaldi, O., Schiavino, D., Perrone, N., Antonietta Frieri, M., Di Rienzo, V., Tripodi, S., Scarpa, A., Tomsic, M., Bonaguro, R., Enrico Senna, G., Sirena, A., Turatello, F., Crescioli, S., Favero, E., Billeri, L., Chieco Bianchi, F., Gemignani, C., Zanforlin, M., Angiola Crivellaro, M., Hendrick, B., Maltauro, A., Masieri, S., Elisabetta Conte, M., Fama, M., Pozzan, M., Bonadonna, P., Casanova, S., Vallerani, E., Schiappoli, M., Borghesan, F., Giro, G., Casotto, S., Berardino, L., Zanoni, G., Ariano, R., Aquilina, R., Pellegrino, R., Marsico, P., Del Giudice, A., Narzisi, G., Tomaselli, V., Fornaca, G., Favro, M., Loperfido, B., Gallo, C., Buffoni, S., Gani, F., Raviolo, P., Faggionato, S., Truffelli, T., Vivalda, L., Albano, M., Enzo Rossi, R., Lattuada, G., Bona, F., Quaglio, L., Chiesa, A., Trapani, M., Seminara, R., Cucchi, B., Oderda, S., Borio, G., Galeasso, G., Garbaccio, P., Marco, A., Marengo, F., Cadario, G., Manzoni, S., Vinay, C., Curcio, A., Silvestri, A., Peduto, A., Riario-Sforza, G. G., Maria Forgnone, A., Barocelli, P., Tartaglia, N., Feyles, G., Giacone, A., Ricca, V., Guida, G., Nebiolo, F., Bommarito, L., Heffler, E., Vietti, F., Galimberti, M., Savi, E., Pappacoda, A., Bottero, P., Porcu, S., Felice, G., Berra, D., Francesca Spina, M., Pravettoni, V., Calamari, A. M., Varin, E., Iemoli, E., Lietti, D., Ghiglioni, D., Alessandro Fiocchi, Tosi, A., Poppa, M., Caviglia, A., Restuccia, M., Russello, M., Alciato, P., Manzotti, G., Ranghino, E., Luraschi, G., Rapetti, A., Rivolta, F., Allegri, F., Terracciano, L., Agostinis, F., Paolo Piras, P., Ronchi, G., Gaspardini, G., Caria, V., Tolu, F., Fantasia, D., Carta, P., Moraschini, A., Quilleri, R., Santelli, A., Prandini, P., Del Giudice, G., Apollonio, A., Bonazza, L., Teresa Franzini, M., Branchi, S., Zanca, M., Rinaldi, S., Catelli, L., Zanoletti, T., Cosentino, C., Della Torre, F., Cremonte, L., Musazzi, D., Suli, C., Rivolta, L., Ottolenghi, A., Marino, G., Sterza, G., Sambugaro, R., Orlandini, A., Minale, P., Voltolini, S., Bignardi, D., Omodeo, P., Tiri, A., Milani, S., Ronchi, B., Licardi, G., Bruni, P., Scibilia, J., Schroeder, J., Crosti, F., Maltagliati, A., Alesina, M. R., Mosca, M., Leone, G., Napolitano, G., Di Gruttola, G., Scala, G., Mascio, S., Valente, A., Marchetiello, I., Catello, R., Gazulli, A., Del Prete, A., Varricchio, A. M., Carbone, A., Forestieri, A., Stillitano, M., Leonetti, L., Tirroni, E., Castellano, F., Abbagnara, F., Romano, F., Levanti, C., Cilia, M., Longo, R., Ferrari, A., Merenda, R., Di Ponti, A., Guercio, E., Surace, L., Ammendola, G., Tansella, F., Peccarisi, L., Stragapede, L., Minenna, M., Granato, M., Fuiano, N., Pannofino, A., Ciuffreda, S., Giannotta, A., Morero, G., D Oronzio, L., Taddeo, G., Nettis, E., Cinquepalmi, G., Lamanna, C., Mastrandrea, F., Minelli, M., Salamino, F., Muratore, L., Latorre, F., Quarta, C., Ventura, M., D Ippolito, G., Giannoccaro, F., Dambra, P., Pinto, L., Triggiani, M., Munno, G., Manfredi, G., Lonero, G., Damiano, V., Errico, G., Di Leo, E., Manzari, F., Spagna, V., Arsieni, A., Matarrese, A., Mazzarella, G., Scarcia, G., Scarano, R., Ferrannini, A., Pastore, A., Maionchi, P., Filannino, L., Tria, M., Giuliano, G., Damiani, E., Scichilone, N., Marchese, M., Lucania, A., Marino, M., Strazzeri, L., Tumminello, S., Vitale, G. I., Gulotta, S., Gragotto, G., Zambito, M., Greco, D., Valenti, G., Licitra, G., Cannata, E., Filpi, R., Contraffatto, M., Sichili, S., Randazzo, S., Scarantino, G., Lo Porto, B., Pavone, F., Di Bartolo, C., Paternò, A., Rapisarda, F., Laudani, E., Leonardi, S., Padua, V., Cabibbo, G., Marino Guzzardi, G., Deluca, F., Agozzino, C., Pettinato, R., Ghini, M., Scurati S., Frati F., Passalacqua G., Puccinelli P., Hilaire C., Incorvaia C., D'Avino G., Comi R., Lo Schiavo M., Pezzuto F., Montera C., Pio A., Teresa Ielpo M., Cellini F., Vicentini L., Pecorari R., Aresu T., Capra L., De Benedictis E., Bombi C., Zauli D., Vanzi A., Alberto Paltrinieri C., Bondioli A., Paletta I., Ventura D., Mei F., Paolini F., Colangelo C., Cavallucci E., Cucinelli F., Tinari R., Ermini G., Beltrami V., Novembre E., Begliomini C., Marchese E., Solito E., Ammannati V., Molino G., Galli E., Baldassini M., Di Michele L., Calvani M., Gidaro M., Venuti A., Li Bianchi E., Benassi F., Pocobelli D., Zangari P., De Rocco M.G., Lo Vecchio A., Pingitore G., Grimaldi O., Schiavino D., Perrone N., Antonietta Frieri M., Di Rienzo V., Tripodi S., Scarpa A., Tomsic M., Bonaguro R., Enrico Senna G., Sirena A., Turatello F., Crescioli S., Favero E., Billeri L., Chieco Bianchi F., Gemignani C., Zanforlin M., Angiola Crivellaro M., Hendrick B., Maltauro A., Masieri S., Elisabetta Conte M., Fama M., Pozzan M., Bonadonna P., Casanova S., Vallerani E., Schiappoli M., Borghesan F., Giro G., Casotto S., Berardino L., Zanoni G., Ariano R., Aquilina R., Pellegrino R., Marsico P., Del Giudice A., Narzisi G., Tomaselli V., Fornaca G., Favro M., Loperfido B., Gallo C., Buffoni S., Gani F., Raviolo P., Faggionato S., Truffelli T., Vivalda L., Albano M., Enzo Rossi R., Lattuada G., Bona F., Quaglio L., Chiesa A., Trapani M., Seminara R., Cucchi B., Oderda S., Borio G., Galeasso G., Garbaccio P., De Marco A., Marengo F., Cadario G., Manzoni S., Vinay C., Curcio A., Silvestri A., Peduto A., Riario-Sforza G.G., Maria Forgnone A., Barocelli P., Tartaglia N., Feyles G., Giacone A., Ricca V., Guida G., Nebiolo F., Bommarito L., Heffler E., Vietti F., Galimberti M., Savi E., Pappacoda A., Bottero P., Porcu S., Felice G., Berra D., Francesca Spina M., Pravettoni V., Calamari A.M., Varin E., Iemoli E., Lietti D., Ghiglioni D., Fiocchi A., Tosi A., Poppa M., Caviglia A., Restuccia M., Russello M., Alciato P., Manzotti G., Ranghino E., Luraschi G., Rapetti A., Rivolta F., Allegri F., Terracciano L., Agostinis F., Paolo Piras P., Ronchi G., Gaspardini G., Caria V., Tolu F., Fantasia D., Carta P., Moraschini A., Quilleri R., Santelli A., Prandini P., Del Giudice G., Apollonio A., Bonazza L., Teresa Franzini M., Branchi S., Zanca M., Rinaldi S., Catelli L., Zanoletti T., Cosentino C., Della Torre F., Cremonte L., Musazzi D., Suli C., Rivolta L., Ottolenghi A., Marino G., Sterza G., Sambugaro R., Orlandini A., Minale P., Voltolini S., Bignardi D., Omodeo P., Tiri A., Milani S., Ronchi B., Licardi G., Bruni P., Scibilia J., Schroeder J., Crosti F., Maltagliati A., Alesina M.R., Mosca M., Leone G., Napolitano G., Di Gruttola G., Scala G., Mascio S., Valente A., Marchetiello I., Catello R., Gazulli A., Del Prete A., Varricchio A.M., Carbone A., Forestieri A., Stillitano M., Leonetti L., Tirroni E., Castellano F., Abbagnara F., Romano F., Levanti C., Cilia M., Longo R., Ferrari A., Merenda R., Di Ponti A., Guercio E., Surace L., Ammendola G., Tansella F., Peccarisi L., Stragapede L., Minenna M., Granato M., Fuiano N., Pannofino A., Ciuffreda S., Giannotta A., Morero G., D'Oronzio L., Taddeo G., Nettis E., Cinquepalmi G., Lamanna C., Mastrandrea F., Minelli M., Salamino F., Muratore L., Latorre F., Quarta C., Ventura M., D'Ippolito G., Giannoccaro F., Dambra P., Pinto L., Triggiani M., Munno G., Manfredi G., Lonero G., Damiano V., Errico G., Di Leo E., Manzari F., Spagna V., Arsieni A., Matarrese A., Mazzarella G., Scarcia G., Scarano R., Ferrannini A., Pastore A., Maionchi P., Filannino L., Tria M., Giuliano G., Damiani E., Scichilone N., Marchese M., Lucania A., Marino M., Strazzeri L., Tumminello S., Vitale G.I., Gulotta S., Gragotto G., Zambito M., Greco D., Valenti G., Licitra G., Cannata E., Filpi R., Contraffatto M., Sichili S., Randazzo S., Scarantino G., Lo Porto B., Pavone F., Di Bartolo C., Paterno A., Rapisarda F., Laudani E., Leonardi S., Padua V., Cabibbo G., Marino Guzzardi G., Deluca F., Agozzino C., Pettinato R., Ghini M., Scurati S, Frati F, Passalacqua G, Puccinelli P, Hilaire C, Incorvaia I, D'Avino G, Comi R, Lo Schiavio M, Pezzuto F, Montera C, Pio A, Ielpo MT, Cellini F, Vicentini L, Pecorari R, Aresu T, Capra L, De Benedictis E, Bombi C, Zauli D, and et al
- Subjects
medicine.medical_specialty ,Pathology ,genetic structures ,efficacy ,Alternative medicine ,Medicine (miscellaneous) ,Adherence, Cost, Efficacy, Side effects, Sublingual immunotherapy ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,sublingual immunotherapy ,ALLERGEN ,cost ,medicine ,Subcutaneous immunotherapy ,Sublingual immunotherapy ,adherence ,Clinical efficacy ,Intensive care medicine ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,sublingual immunoterapy ,Original Research ,Asthma ,AEROALLERGENS ,side effects ,business.industry ,Health Policy ,medicine.disease ,Slit ,eye diseases ,Clinical trial ,Patient Preference and Adherence ,immunotherapy ,sense organs ,Allergists ,ADHERENCE TO TREATMENT ,business ,Social Sciences (miscellaneous) - Abstract
Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered by patients without medical supervision, the degree of patient adherence with treatment is still a concern. The objective of this study was to evaluate the perception by allergists of issues related to SLIT adherence.Methods: We performed a questionnaire-based survey of 296 Italian allergists, based on the adherence issues known from previous studies. The perception of importance of each item was assessed by a VAS scale ranging from 0 to 10.Results: Patient perception of clinical efficacy was considered the most important factor (ranked 1 by 54% of allergists), followed by the possibility of reimbursement (ranked 1 by 34%), and by the absence of side effects (ranked 1 by 21%). Patient education, regular follow-up, and ease of use of SLIT were ranked first by less than 20% of allergists.Conclusion: These findings indicate that clinical efficacy, cost, and side effects are perceived as the major issues influencing patient adherence to SLIT, and that further improvement of adherence is likely to be achieved by improving the patient information provided by prescribers.Keywords: adherence, sublingual immunotherapy, efficacy, cost, side effects
- Published
- 2010
13. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders
- Author
-
Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM, Ciavarella N, Valdrè L, Targhetta R, Biasioli C, Vincenzi D, Molinari C, Boeri E, Mariani G, Lapecorella M, Coppola A, Schiavulli M, Rocino A, Mancuso G, Siragusa S, Malato A, Tagliaferri A, Rivolta F, Oliovecchio E, Marcucci M, Dragani A, Mancino A, D'Incà M, De Rossi G, Luciani M, Landolfi R, Piseddu G, Schinco PC, Rossetti G, Barillari G, Feola G, Gandini G, Giuffrida A, Castaman G., DI MINNO, GIOVANNI, Tagariello, G, Iorio, A, Santagostino, E, Morfini, M, Bisson, R, Innocenti, M, Mancuso, ME, Mazzucconi, MG, Pasta, GL, Radossi, P, Rodorigo, G, Santoro, C, Sartori, R, Scaraggi, A, Solimeno, LP, Mannucci, PM, Ciavarella, N, Valdrè, L, Targhetta, R, Biasioli, C, Vincenzi, D, Molinari, C, Boeri, E, Mariani, G, Lapecorella, M, di Minno, G, Coppola, A, Schiavulli, M, Rocino, A, Mancuso, G, Siragusa, S, Malato, A, Tagliaferri, A, Rivolta, F, Oliovecchio, E, Marcucci, M, Dragani, A, Mancino, A, D'Incà, M, De Rossi, G, Luciani, M, Landolfi, R, Piseddu, G, Schinco, PC, Rossetti, G, Barillari, G, Feola, G, Gandini, G, Giuffrida, A, Castaman, G, Mancuso, Me, Mazzucconi, Mg, Pasta, Gl, Solimeno, Lp, Mannucci, Pm, DI MINNO, Giovanni, Schinco, Pc, and Castaman, G.
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Immunology ,Population ,macromolecular substances ,Gene mutation ,Hemophilia A ,Hemophilia B ,Severity of Illness Index ,Biochemistry ,Arthroplasty ,Settore MED/15 - Malattie Del Sangue ,Cohort Studies ,Young Adult ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,Severity of illness ,medicine ,Coagulopathy ,Humans ,Child ,education ,Retrospective Studies ,education.field_of_study ,Hematology ,hamophilia, arthroplasty ,business.industry ,Retrospective cohort study ,Cell Biology ,Odds ratio ,Blood Coagulation Disorders ,Middle Aged ,medicine.disease ,Surgery ,Italy ,Joint Diseases ,business ,Algorithms - Abstract
Data from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and inhibitor in a Cox regression model (HR, 2.65; 95% CI, 1.62-4.33; P < .001). The survival analysis of time to joint arthroplasty in the subset of patients with severe HA was not affected by the severity of factor VIII (FVIII) gene mutations. A systematic review of literature articles reporting joint arthroplasties in HA and HB showed that the proportion of HA patients who had undergone arthroplasties was higher than that of HB patients, in agreement with the findings in our Italian cohort. These data suggest that the 2 inherited coagulation disorders have a different severity of clinical phenotype.
- Published
- 2009
14. Evidence-based recommendations on the treatment of von Willebrand disease in Italy
- Author
-
Mannucci, Pm, Franchini, M, Castaman, G, Federici, Ab, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdre, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Boeri, E, Caprino, D, Delios, G, Girotto, M, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Marietta, M, Pedrazzoli, P, Di Minno, G, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Iorio, A, Oliovecchio, E, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, D'Incà, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Maria Gabriella, Santoro, Cristina, Piseddu, G, Schinco, Pc, Rossetti, G, Barillari, G, Feola, G, Gandini, G., Mannucci, Pm, Franchini, M, Castaman, G, Federici, Ab, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdre, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Morfini, M, Molinari, Ac, Boeri, E, Caprino, D, Delios, G, Girotto, M, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Marietta, M, Pedrazzoli, P, DI MINNO, Giovanni, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Iorio, A, Oliovecchio, E, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, D'Incà, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Mg, Santoro, C, Piseddu, G, Schinco, Pc, Rossetti, G, Barillari, G, Feola, G, and Gandini, G.
- Subjects
Male ,desmopressin ,Evidence-Based Medicine ,Factor VIII ,Hemostatics ,von willebrand disease ,von Willebrand Diseases ,von willebrand factor ,Treatment Outcome ,Italy ,von Willebrand Factor ,Humans ,Deamino Arginine Vasopressin ,Drug Therapy, Combination ,Female ,Original Article - Abstract
von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissues. The aim of treatment is to correct the dual defect of haemostasis caused by the abnormal/reduced VWF and the concomitant deficiency of factor VIII (FVIII).This document contains evidence-based recommendations for the management of VWD compiled by AICE (the Italian Association of Haemophilia Centres). All the evidence supporting these recommendations are based on non-randomised comparative studies or case series, because randomised controlled clinical trials or meta-analyses are not available for this disease.Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD with FVIII and VWF levels of 10 U/dL or more, while VWF/FVIII concentrates are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2 and 3 VWD). VWF concentrates devoid of FVIII, not yet licensed in Italy, may be considered for short-term prophylaxis in elective surgery or for long-term secondary prophylaxis.
- Published
- 2009
15. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis
- Author
-
IORIO A, OLIOVECCHIO E, MORFINI M, MANNUCCI PM, CONTINO L, ACCORSI A, CIAVARELLA N, SCHIAVONI M, SCARAGGI FA, RODORIGO G, VALDRÉ L, TARGHETTA R, TAGARIELLO G, RADOSSI P, MUSSO R, CULTRERA D, MULEO G, IANNACARO P, BIASIOLI C, TESTA S, ALATRI A, VINCENZI D, SCAPOLI G, MOLINARI AC, BOERI E, CAPRINO D, MARIANI G, LAPECORELLA M, CARLONI MT, CANTORI I, SANTAGOSTINO E, GRINGERI A, FEDERICI AB, MARIETTA M, PEDRAZZOLI P, DI MINNO G, PERRICONE C, SCHIAVULLI M, ROCINO A, BERRETTINI M, ZANON E, MANCUSO G, TAGLIAFERRI A, RIVOLTA F, FERRANTE F, DRAGANI A, ROSSI A, ALBERTINI P, MACCHI S, D'INCA M, DE ROSSI G, LUCIANI M, LANDOLFI R, MAZZUCCONI MG, SANTORO C, PISEDDU G, CARLA SCHINCO P, ROSSETTI G, BARILLARI G, FEOLA G, GANDINI G, FRANCHINI M, CASTAMAN G., COPPOLA, Antonino, SIRAGUSA, Sergio, MALATO, Alessandra, SACCULLO, Giorgia, MANCINO, Antonio, IORIO A, OLIOVECCHIO E, MORFINI M, MANNUCCI PM, CONTINO L, ACCORSI A, CIAVARELLA N, SCHIAVONI M, SCARAGGI FA, RODORIGO G, VALDRÉ L, TARGHETTA R, TAGARIELLO G, RADOSSI P, MUSSO R, CULTRERA D, MULEO G, IANNACARO P, BIASIOLI C, TESTA S, ALATRI A, VINCENZI D, SCAPOLI G, MOLINARI AC, BOERI E, CAPRINO D, MARIANI G, LAPECORELLA M, CARLONI MT, CANTORI I, SANTAGOSTINO E, GRINGERI A, FEDERICI AB, MARIETTA M, PEDRAZZOLI P, DI MINNO G, COPPOLA A, PERRICONE C, SCHIAVULLI M, ROCINO A, BERRETTINI M, ZANON E, MANCUSO G, SIRAGUSA S, MALATO A, SACCULLO G, TAGLIAFERRI A, RIVOLTA F, FERRANTE F, DRAGANI A, ROSSI A, MANCINO A, ALBERTINI P, MACCHI S, D'INCA M, DE ROSSI G, LUCIANI M, LANDOLFI R, MAZZUCCONI MG, SANTORO C, PISEDDU G, CARLA SCHINCO P, ROSSETTI G, BARILLARI G, FEOLA G, GANDINI G, FRANCHINI M, and CASTAMAN G
- Subjects
methodology, haemophilia ,Settore MED/15 - Malattie Del Sangue - Published
- 2008
16. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis
- Author
-
Iorio, A, Oliovecchio, E, Morfini, M, Mannucci, Pm, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdré, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Molinari, Ac, Boeri, E, Caprino, D, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Federici, Ab, Marietta, M, Pedrazzoli, P, Di Minno, G, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, Hassan, J, D'Inca, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Maria Gabriella, Santoro, Cristina, Piseddu, G, Carla Schinco, P, Rossetti, G, Barillari, G, Feola, G, Gandini, G, Franchini, M, Castaman, G., Iorio, A, Oliovecchio, E, Morfini, M, Mannucci, Pm, Contino, L, Accorsi, A, Ciavarella, N, Schiavoni, M, Scaraggi, Fa, Rodorigo, G, Valdré, L, Targhetta, R, Tagariello, G, Radossi, P, Musso, R, Cultrera, D, Muleo, G, Iannacaro, P, Biasioli, C, Testa, S, Alatri, A, Vincenzi, D, Scapoli, G, Molinari, Ac, Boeri, E, Caprino, D, Mariani, G, Lapecorella, M, Carloni, Mt, Cantori, I, Santagostino, E, Gringeri, A, Federici, Ab, Marietta, M, Pedrazzoli, P, DI MINNO, Giovanni, Coppola, A, Perricone, C, Schiavulli, M, Rocino, A, Berrettini, M, Zanon, E, Mancuso, G, Siragusa, S, Malato, A, Saccullo, G, Tagliaferri, A, Rivolta, F, Ferrante, F, Dragani, A, Rossi, A, Mancino, A, Albertini, P, Macchi, S, Hassan, J, D'Inca, M, De Rossi, G, Luciani, M, Landolfi, R, Mazzucconi, Mg, Santoro, C, Piseddu, G, Carla Schinco, P, Rossetti, G, Barillari, G, Feola, G, Gandini, G, Franchini, M, and Castaman, G.
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Haemophilia A ,MEDLINE ,Haemophilia ,Severity of Illness Index ,haemophilia ,registry ,von willebrand's disease ,von willebrand’s disease ,Blood Coagulation Disorders, Inherited ,Von willebrand ,Severity of illness ,Health care ,Computer software ,medicine ,Humans ,Haemophilia B ,Registries ,Age of Onset ,Child ,Genetics (clinical) ,Societies, Medical ,Aged ,business.industry ,Infant ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Databases as Topic ,Italy ,Child, Preschool ,Data Interpretation, Statistical ,Female ,Medical emergency ,business - Abstract
National haemophilia registries are powerful instruments to support health care and research. A national registry was established in Italy by the Ministry of Health until 1999. Since 2003 the Italian Association of Haemophilia Centres (AICE) started a new programme aiming at building up the Italian Registry of Haemophilia and Allied Disorders. The AICE identified an expert panel to steer the registry. A computer software to assist patient management was developed and all the AICE-affiliated haemophilia treatment centres (HTC) were prompted to adopt it. Twice a year a predefined set of anonymized data is centralized and merged into a national database. Duplicated entries are managed through a confidentiality sparing mechanism. The database covers sociodemographic, clinical, laboratory and treatment data. A subset of data are shared with the Ministry of Health (Istituto Superiore di Sanita,ISS).Overall, data were collected six times by 43 of 49 HTC; 41 centres updated their patients' records up to December 2006. The database contains 6632 unique records, 442 of them referring to dead patients. Database growth and missing data clearance showed a constantly positive trend over time. The database has collected records of the following alive patients - haemophilia A: 1364 severe, 398 moderate and 935 mild; haemophilia B: 231 severe, 138 moderate and 204 mild; von Willebrand's disease: 1208 type 1, 346 type 2 and 96 type 3. Inhibitor patients were 296 (of which 194 high responders and 65 low responders).The Italian registry run by AICE adds to the list of the available national haemophilia registries and is intended to establish treatment guidelines and foster research projects in Italy.
- Published
- 2008
17. Advanced Cuttings Analysis Improves Reservoir Characterisation and Reduces Operating Times in Shale Gas Drilling Project
- Author
-
Carugo, C., additional, Malossi, A., additional, Balossino, P., additional, Galimberti, R., additional, Gioacchini, L., additional, Rivolta, F., additional, Previde Massara, E., additional, and Pingitore, F., additional
- Published
- 2013
- Full Text
- View/download PDF
18. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
- Author
-
Rossini, F, Terruzzi, E, Perego, D, Miccolis, I, Rivolta, F, Manca, E, Pogliani, E, POGLIANI, ENRICO MARIA, Rossini, F, Terruzzi, E, Perego, D, Miccolis, I, Rivolta, F, Manca, E, Pogliani, E, and POGLIANI, ENRICO MARIA
- Abstract
Doxorubicin cardiotoxicity is one of the most serious side effects of the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, regimen, especially among elderly patients. In the CEOP regimen, epirubicin was substituted for doxorubicin to reduce cardiotoxicity.
- Published
- 2004
19. ChemInform Abstract: Baker′s Yeast Mediated Biohydrogenation of 2-Substituted Allyl Alcohols: Synthesis of Enantiomerically Pure (2S)-3-Benzyloxy-2-methyl- 1-propanol.
- Author
-
FERRABOSCHI, P., primary, ELAHI, S. R., additional, VERZA, E., additional, RIVOLTA, F. M., additional, and SANTANIELLO, E., additional
- Published
- 2010
- Full Text
- View/download PDF
20. L-Asparaginase in Acute Lymphoblastic Leukemia Treatment: The Role of Human Antithrombin III Concentrates in Regulating the Prothrombotic State Induced by Therapy
- Author
-
Pogliani, E.M., primary, Parma, M., additional, Baragetti, I., additional, Mostarda, G., additional, Rivolta, F., additional, Maffé, P., additional, and Corneo, G., additional
- Published
- 1995
- Full Text
- View/download PDF
21. Incidence of anaphylaxis in the emergency department of a general hospital in Milan
- Author
-
Pastorello, E. A., Rivolta, F., Bianchi, M., Mauro, M., and Pravettoni, V.
- Published
- 2001
- Full Text
- View/download PDF
22. The major allergen of sesame seeds (Sesamum indicum) is a 2S albumin
- Author
-
Pastorello, E. A., Varin, E., Farioli, L., Pravettoni, V., Ortolani, C., Trambaioli, C., Fortunato, D., Giuffrida, M. G., Rivolta, F., and Robino, A.
- Published
- 2001
- Full Text
- View/download PDF
23. Clinical role of a lipid transfer protein that acts as a new apple-specific allergen
- Author
-
Pastorello, E.A., Pravettoni, V., Farioli, L., Ispano, M., Fortunato, D., Monza, M., Giuffrida, M.G., Rivolta, F., Scibola, E., Ansaloni, R., Incorvaia, C., Conti, A., and Ortolani, C.
- Abstract
Background: Allergy to apple is commonly associated with birch pollinosis because the two share homologous allergens. However, some patients have apple allergy but no birch pollinosis, suggesting that there are allergens that do not cross-react with birch. Objective: The aim of the study was to evaluate the IgE reactivity pattern to an apple extract in subjects with allergic reactions to apple, with and without birch hay fever. Methods: Forty-three patients with oral allergy syndrome for apple and positive open food challenge, skin prick test, and serum specific IgE antibodies to apple were admitted to the study. Thirty-two had birch pollinosis (documented by specific IgE for birch) and 11 were not allergic to birch. The IgE reactivity pattern to apple extract was identified by SDS-PAGE and immunoblotting. The consistent allergen, a 9-kd protein, was then purified by HPLC and characterized by periodic acid-Schiff staining, isoelectric point, and N-terminal amino acid sequencing. Results: The sera from 28% of patients allergic to apple with birch pollinosis, but from all patients allergic only to apple, recognized the 9-kd protein. This protein has an isoelectric point of 7.5 and is not glycosylated. Determination of its partial amino acid sequence showed that it belongs to the family of lipid transfer proteins, which act as major allergens in Prunoideae fruits. Conclusions: These results indicate that a lipid transfer protein is an important allergen in patients allergic to apple but not to birch pollen. The prevalent IgE reactivity to this allergen in subjects with no birch pollinosis and the physicochemical characteristics of this protein suggest that sensitization may occur through the oral route. (J Allergy Clin Immunol 1999;104:1099-106.)
- Published
- 1999
- Full Text
- View/download PDF
24. Sensitization to the major allergen of Brazil nut is correlated with the clinical expression of allergy
- Author
-
Pastorello, E.A., Farioli, L., Pravettoni, V., Ispano, M., Conti, A., Ansaloni, R., Rotondo, F., Incorvaia, C., Bengtsson, A., Rivolta, F., Trambaioli, C., Previdi, M., and Ortolani, C.
- Abstract
Background: Only a few studies have investigated the clinical role of food allergens, especially the relationship between sensitization to a given allergen and occurrence of adverse reactions when eating the relevant food item. Objective: This study evaluated the clinical role of the allergens of Brazil nut by comparing the patterns of IgE binding in sera from 11 patients with anaphylaxis after eating Brazil nuts with those from 10 subjects with no symptoms to this food item. Both groups had specific IgE to Brazil nut. Methods: Allergens in the in-house extract of Brazil nut were identified by SDS-PAGE/immunoblotting, the major allergen was purified by HPLC, and its N-terminal sequence was determined by a protein sequencer. Results: SDS-PAGE/immunoblotting detected a number of allergenic components with molecular weights ranging from 4 to 58 kd. All sera from symptomatic patients recognized a 9-kd allergen corresponding (as established by amino acid sequencing) to a 2S albumin already described as a major allergen of Brazil nut, whereas the other allergens each bound IgE from less than 50% of sera. No sera from asymptomatic subjects showed IgE binding to the 9-kd allergen, but they did recognize components from 25 to 58 kd, which are minor allergens. Conclusions: These findings indicate that the allergen underlying clinical reactions to Brazil nut is a 2S albumin of 9 kd and that in vitro reactivity to this allergen identifies subjects who react in vivo to ingestion of this food. (J Allergy Clin Immunol 1998;102:1021-7.)
- Published
- 1998
- Full Text
- View/download PDF
25. ChemInform Abstract: Baker′s Yeast Mediated Biohydrogenation of 2-Substituted Allyl Alcohols: Synthesis of Enantiomerically Pure (2S)-3-Benzyloxy-2-methyl- 1-propanol.
- Author
-
FERRABOSCHI, P., ELAHI, S. R., VERZA, E., RIVOLTA, F. M., and SANTANIELLO, E.
- Published
- 1997
- Full Text
- View/download PDF
26. Ragweed pollen concentration predicts seasonal rhino-conjunctivitis and asthma severity in patients allergic to ragweed
- Author
-
Maira, Bonini, Gianna Serafina, Monti, Matteo Maria, Pelagatti, Valentina, Ceriotti, Elisabetta Elena, Re, Barbara, Bramè, Paolo, Bottero, Anna, Tosi, Adriano, Vaghi, Alberto, Martelli, Giovanni Maria, Traina, Loredana, Rivolta, Federica, Rivolta, Claudio Maria, Ortolani, Bonini, M, Monti, G, Pelagatti, M, Ceriotti, V, Re, E, Bramè, B, Bottero, P, Tosi, A, Vaghi, A, Martelli, A, Traina, G, Rivolta, L, Rivolta, F, and Ortolani, C
- Subjects
Respiratory tract diseases ,Multidisciplinary ,Plant Extracts ,Rhinitis, Allergic, Seasonal ,Allergens ,Antigens, Plant ,Conjunctivitis ,Asthma ,Environmental science ,Environmental impact ,SECS-S/01 - STATISTICA ,Humans ,Seasons ,Ambrosia - Abstract
In this work, we investigate the correlation between ragweed pollen concentration and conjunctival, nasal, and asthma symptom severity in patients allergic to ragweed pollen using ambient pollen exposure in the Milan area during the 2014 ragweed season We calculate the pollen/symptom thresholds and we assess the effectiveness of ragweed allergen immunotherapy (AIT). A total of 66 participants allergic to ragweed (Amb a 1) were enrolled in the study and divided into two groups: AIT treated (24) and no AIT treated (42). Pollen counts and daily symptom/medication patient diaries were kept. Autoregressive distributed lag models were used to develop predictive models of daily symptoms and evaluate the short-term effects of temporal variations in pollen concentration on the onset of symptoms. We found significant correlations between ragweed pollen load and the intensity of symptoms for all three symptom categories, both in no AIT treated (τ = 0.341, 0.352, and 0.721; and ρ = 0.48, 0.432, and 0.881; p-value $$\tau$$ τ = 0.46, 0.610, and 0.66; and ρ = 0.692, 0.805, and 0.824; p-value
- Published
- 2022
27. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
- Author
-
Isabella Miccolis, Daniele Perego, Elisabetta Terruzzi, Elena Manca, Franca Rivolta, Enrico M. Pogliani, Fausto Rossini, Rossini, F, Terruzzi, E, Perego, D, Miccolis, I, Rivolta, F, Manca, E, and Pogliani, E
- Subjects
Male ,Adult ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Adolescent ,Cyclophosphamide ,medicine.medical_treatment ,Comorbidity ,Gastroenterology ,Follow-Up Studie ,International Prognostic Index ,MED/15 - MALATTIE DEL SANGUE ,Prednisone ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Epirubicin ,Aged ,Chemotherapy ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Lymphoma, Non-Hodgkin ,Middle Aged ,Chemotherapy regimen ,Surgery ,Survival Rate ,Regimen ,Oncology ,Female ,business ,Follow-Up Studies ,Human ,medicine.drug - Abstract
BACKGROUND Doxorubicin cardiotoxicity is one of the most serious side effects of the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, regimen, especially among elderly patients. In the CEOP regimen, epirubicin was substituted for doxorubicin to reduce cardiotoxicity. METHODS Between March 1984 and September 1998, 186 previously untreated patients with a histologically confirmed diagnosis of intermediate- or high-grade non-Hodgkin lymphoma according to the Working Formulation were treated with CEOP (cyclophosphamide, 750 mg/m2, epirubicin, 75 mg/m2, vincristine, 1.4 mg/m2; and prednisone, 60 mg per day orally on Days 1–5). Of 186 patients, 85 (45.7%) had Stage IV disease, and 60 (32.3%) had an International Prognostic Index score > 2. Comorbidity was present in 36 patients (19.3%). RESULTS Complete remission (CR) was achieved in 119 patients (64.3%), and partial remission was achieved in 30 patients (16.2%). Among the patients who achieved a CR, 95 (79.8%) were still disease free at a median follow-up time of 86.9 months (range, 14–200 months). The remaining 24 patients experienced disease recurrence, at a median follow-up time of 19 months (range, 3–101 months). The relative dose intensities were 0.69, 0.89, and 0.80 for vincristine, epirubicin, and cyclophosphamide, respectively. Two patients died of toxicity due to infection. Two patients, 59 and 73 years old, respectively, experienced arrhythmia. Another patient, age 64 years, who had a myocardial infarction 10 years earlier, had angina. One patient with hypertension experienced cardiac failure. No patients died of cardiac toxicity. CONCLUSION Long-term follow-up confirmed that CEOP is an effective and well-tolerated chemotherapy regimen for intermediate- and high-grade lymphoma. The Results were promising, especially among elderly patients. Cancer 2004;100:350–5. © 2003 American Cancer Society.
- Published
- 2004
- Full Text
- View/download PDF
28. Quality of Life in Hymenoptera Venom Allergy: Minimal Clinically Important Difference for the Vespid Quality of Life Questionnaire.
- Author
-
Martini M, Mauro M, Bignardi D, Bonadonna P, Braschi MC, Emiliani F, Guerra L, Liberati S, Olivieri F, Pravettoni V, Preziosi D, Ridolo E, Rivolta F, Baiardini I, and Bilò MB
- Published
- 2024
- Full Text
- View/download PDF
29. The first case of erythritol-induced anaphylaxis in Europe diagnosed with skin tests and basophil activation tests.
- Author
-
Dubini M, Pignatti P, Rivolta F, Gurrado A, and Marraccini P
- Abstract
The use of erythritol as a food sweetener has spread significantly from Japan throughout the world. We describe a case of severe anaphylaxis due to immediate-type allergy to erythritol that was diagnosed with in vitro basophil activation tests and in vivo skin tests., Competing Interests: Partially supported by the 10.13039/501100003196Italian Ministry of Health, Current Research IRCCS. Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.
- Author
-
Sciumè M, Serpenti F, Zanotti R, Bonadonna P, Tanasi I, Crosera L, Elena C, Mannelli F, Crupi F, Papayannidis C, Sartor C, Soverini S, Rondoni M, Eller-Vainicher C, Pravettoni V, Rivolta F, Alberti Violetti S, Croci GA, Migliorini AC, Bolli N, Giannarelli D, and Grifoni FI
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, World Health Organization, Adult, Mastocytosis, Systemic diagnosis, Mastocytosis, Systemic pathology
- Published
- 2024
- Full Text
- View/download PDF
31. Acetylsalicylic acid desensitization in an allergic pregnant woman post-vascular scaffolds implantation.
- Author
-
Rivolta F, Chiei Gallo A, Sangalli A, and Pravettoni V
- Subjects
- Female, Pregnancy, Humans, Aspirin adverse effects, Pregnant People, Desensitization, Immunologic methods, Anti-Inflammatory Agents, Non-Steroidal, Drug Hypersensitivity diagnosis, Drug Hypersensitivity therapy, Coronary Artery Disease therapy
- Abstract
Summary: The use of acetylsalicylic acid (ASA) desensitization for patients with coronary artery disease (CAD) is growing, but no data are available on desensitization protocol in patients with ASA sensitivity and CAD during pregnancy. This case report shows that ASA desensitization protocol during pregnancy could be safe and effective in a tertiary centre with a multidisciplinary team.
- Published
- 2024
- Full Text
- View/download PDF
32. The role of skin tests with polyethylene glycol and polysorbate 80 in the vaccination campaign for COVID-19: results from an Italian multicenter survey.
- Author
-
Montera MC, Giordano A, Asperti C, Aruanno A, Barzaghi CE, Bignardi D, Borrelli P, Bommarito L, Busa M, Calafiore P, Carusi V, Cinquini M, Cortellini G, Cocchi R, D'Auria F, De Caro F, Demonte A, Di Leo E, Di Lizia M, Di Rienzo A, Fumagalli F, Kihlgren P, Lodi Rizzini F, Macchia D, Manzotti G, Marra AM, Mileto P, Mietta S, Montagni M, Nettis E, Nucera E, Peveri S, Pivetta D, Pirisi M, Ramirez GA, Rivolta F, Rizzi A, Savoia A, Pedicini A, Scarpa A, Zambito M, Zisa G, and Yacoub MR
- Subjects
- Humans, Polysorbates adverse effects, Polyethylene Glycols adverse effects, COVID-19 Vaccines adverse effects, Excipients adverse effects, Retrospective Studies, Immunization Programs, Skin Tests, Italy epidemiology, COVID-19 epidemiology, COVID-19 prevention & control, Anaphylaxis diagnosis, Anaphylaxis epidemiology, Hypersensitivity, Immediate
- Abstract
Summary: Background. International guidelines suggested skin tests with Polyethylene-glycol (PEG) and polysorbate 80 (PS-80), to investigate a possible hypersensitivity to these excipients either to identify subjects at risk of developing allergic reactions to Covid-19 vaccines, or in patients with suspected IgE mediated hypersensitivity reactions (HR) to the Covid-19 vaccine. The main purpose of this study was to investigate the prevalence of PEG and PS sensitization in patients with a clinical history of HR to drugs containing PEG/PS and in patients with a suspected Covid-19 vaccine immediate HR. Methods. This was a multicenter retrospective study conducted by allergists belonging to 20 Italian medical centers. Skin testing was performed in 531 patients with either a clinical history of suspected hypersensitivity reaction (HR) to drugs containing PEG and/or PS-80 (group 1:362 patient) or a suspected HR to Covid-19 vaccines (group 2: 169 patient), as suggested by the AAIITO/SIAAIC guidelines for the "management of patients at risk of allergic reactions to Covid-19 vaccines" [1]. Results. 10/362 (0.02%) had positive skin test to one or both excipients in group 1, 12/169 (7.1%) in group 2 (p less than 0.01). In group 2 HRs to Covid-19 vaccines were immediate in 10/12 of cases and anaphylaxis occurred in 4/12 of patients. Conclusions. The positivity of skin test with PEG and or PS before vaccination is extremely rare and mostly replaceable by an accurate clinical history. Sensitization to PEG and PS has to be investigated in patients with a previous immediate HR to a Covid-19 vaccine, in particular in patients with anaphylaxis.
- Published
- 2024
- Full Text
- View/download PDF
33. Asthma improvement in patients treated with dupilumab for severe atopic dermatitis.
- Author
-
Dubini M, Benzecry V, Rivolta F, Sangalli A, Marzano AV, Pravettoni V, Tavecchio S, and Ferrucci SM
- Abstract
Introduction: Atopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to prospectively evaluate the respiratory outcomes in patients with persistent allergic asthma treated with dupilumab due to severe AD (sAD)., Methods: We enrolled eligible patients with sAD for dupilumab treatment from September 2018 to December 2020. We then selected the subgroup of patients sensitized to perennial allergens. Dupilumab's efficacy and safety on AD and comorbid asthma were assessed at baseline, one month, four months, and then every 4 months up to one year., Results: A total of 437 patients with sAD were enrolled for dupilumab treatment due to sAD, and 273 reached 48 weeks of therapy. Respiratory outcomes were evaluated in the 85 asthmatic patients with positivity only to perennial allergens. Our patients showed statistically and clinically significant improvement in asthma control (Asthma Control Test and Asthma Control Questionnaire) and airway obstruction parameters (FEV1), in addition to the expected AD-related skin outcomes. Specifically, a significant improvement was achieved at the fourth month of dupilumab therapy, and this trend was maintained up to twelve months, regardless of asthma severity., Conclusions: Our results showed the overall improvement of the clinical picture that dupilumab offers for patients with severe AD and persistent allergic asthma of any severity, highlighting the importance of a global multidisciplinary approach of type 2 driven disease., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Dubini, Benzecry, Rivolta, Sangalli, Marzano, Pravettoni, Tavecchio and Ferrucci.)
- Published
- 2023
- Full Text
- View/download PDF
34. Successful adalimumab graded challenge after allergic delayed reaction to golimumab in a woman with rheumatoid arthritis.
- Author
-
Rivolta F, Sangalli A, Cappelletti C, Chiei Gallo A, Dubini M, and Pravettoni V
- Abstract
A graded challenge with adalimumab could be safe in case of a delayed allergic reaction to golimumab, after a detailed allergological evaluation and the exclusion of allergic sensitization using skin tests., Competing Interests: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript., (© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
35. Successful fractionated undiluted doses of COVID-19 vaccine in five cases of suspected allergic reactions to the first dose.
- Author
-
Rivolta F, Camilla C, Sangalli A, Chiei Gallo A, and Pravettoni V
- Abstract
After a suspected allergic reaction to first dose of mRNA COVID-19 vaccine, given the PEG skin tests negativity and tolerance in vivo to PEG containing drugs, five patients were vaccinated with the second dose of Pfizer-Biontech undergoing a fractional protocol, with antihistamine premedication, without presenting immediate or delayed reactions., Competing Interests: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript., (© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
36. Venom immunotherapy: safety and tolerability of the build-up phase with depot versus aqueous preparations.
- Author
-
Pravettoni V, Mauro M, Rivolta F, Consonni D, Cappelletti C, Chiei Gallo A, Sangalli A, and Bilò MB
- Subjects
- Humans, Immunotherapy, Wasp Venoms, Bee Venoms, Desensitization, Immunologic adverse effects
- Published
- 2022
- Full Text
- View/download PDF
37. Ragweed pollen concentration predicts seasonal rhino-conjunctivitis and asthma severity in patients allergic to ragweed.
- Author
-
Bonini M, Monti GS, Pelagatti MM, Ceriotti V, Re EE, Bramè B, Bottero P, Tosi A, Vaghi A, Martelli A, Traina GM, Rivolta L, Rivolta F, and Ortolani CM
- Subjects
- Ambrosia, Antigens, Plant, Humans, Plant Extracts, Seasons, Allergens, Asthma chemically induced, Asthma therapy, Conjunctivitis chemically induced, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
In this work, we investigate the correlation between ragweed pollen concentration and conjunctival, nasal, and asthma symptom severity in patients allergic to ragweed pollen using ambient pollen exposure in the Milan area during the 2014 ragweed season We calculate the pollen/symptom thresholds and we assess the effectiveness of ragweed allergen immunotherapy (AIT). A total of 66 participants allergic to ragweed (Amb a 1) were enrolled in the study and divided into two groups: AIT treated (24) and no AIT treated (42). Pollen counts and daily symptom/medication patient diaries were kept. Autoregressive distributed lag models were used to develop predictive models of daily symptoms and evaluate the short-term effects of temporal variations in pollen concentration on the onset of symptoms. We found significant correlations between ragweed pollen load and the intensity of symptoms for all three symptom categories, both in no AIT treated (τ = 0.341, 0.352, and 0.721; and ρ = 0.48, 0.432, and 0.881; p-value < 0.001) and in AIT treated patients ([Formula: see text]= 0.46, 0.610, and 0.66; and ρ = 0.692, 0.805, and 0.824; p-value < 0.001). In both groups, we observed a positive correlation between the number of symptoms reported and drug use. Mean symptom levels were significantly higher in no AIT treated than in AIT treated patients (p-value < 0.001) for all symptom categories. Pollen concentration thresholds for the four symptom severity levels (low, medium-low, medium-high and high) were calculated. Ragweed pollen concentration is predictive of symptom severity in patients with a ragweed (Amb a 1) allergy. Patients treated with AIT had significantly reduced mean symptom levels compared to those without AIT., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
38. Mollusk allergy in shrimp-allergic patients: Still a complex diagnosis. An Italian real-life cross-sectional multicenter study.
- Author
-
Scala E, Abeni D, Aruanno A, Boni E, Brusca I, Cappiello F, Caprini E, Buzzulini F, Deleonardi G, Demonte A, Farioli L, Lodi Rizzini F, Michelina Losappio L, Macchia D, Manzotti G, Meneguzzi G, Montagni M, Nucera E, Onida R, Pastorello EA, Peveri S, Radice A, Rivolta F, Rizzi A, Giani M, Cecchi L, Pinter E, Miglionico M, Vantaggio L, Pravettoni V, Villalta D, and Asero R
- Abstract
Introduction: Shellfish allergy is an important cause of food allergies worldwide. Both in vivo and in vitro diagnostics failure nowadays is caused by the poor quality of the extracts associated with the scarce availability of allergenic molecules in the market. It is known that not all patients with shellfish allergies experience adverse reactions to mollusks. It is still unclear how to detect and diagnose these patients correctly., Aim: To investigate the features of shrimp-allergic patients either reactive or tolerant to mollusks, with the currently available diagnostic methods., Methods: Nineteen centers, scattered throughout Italy, participated in the real-life study, enrolling patients allergic to shrimp with or without associated reactions to mollusks. Patients underwent skin tests using commercial extracts or fresh raw and cooked shrimp and mollusks, and IgE reactivity to currently available allergenic extracts and molecules was measured in vitro ., Results: Two hundred and forty-seven individuals with a self reported adverse reactions to shrimp participated in the study; of these 47.8% reported an adverse reaction to mollusks ingestion (cephalopod and/or bivalve). Neither of the tests used, in vivo nor in vitro , was able to detect all selected patients. Accordingly, a great heterogeneity of results was observed: in vivo and in vitro tests agreed in 52% and 62% of cases. Skin tests were able to identify the mollusk reactors (p < 0.001), also using fresh cooked or raw food (p < 0.001). The reactivity profile of mollusk reactors was dominated by Pen m 1, over Pen m 2 and Pen m 4 compared to tolerant subjects, but 33% of patients were not detected by any of the available molecules. Overall, a higher frequency of IgE rectivity to shrimp was recorded in northern Italy, while mollusk reactivity was more frequent in the center-south., Conclusion: The current diagnostic methods are inadequate to predict the cross-reactivity between crustaceans and mollusks. The detection of mollusks hypersensitivity should still rely on skin tests with fresh material. The exclusion of mollusks from shrimp allergic patients' diets should occur when clinical history, available diagnostic instruments, and/or tolerance tests support such a decision., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
39. A comprehensive molecular approach in fish allergy: Usefulness in daily clinical practice.
- Author
-
Villalta D, Scala E, Deleonardi G, Busa M, Rivolta F, Boni E, Gabrielli G, Farioli L, Cappelletti C, Buzzulini F, Conte M, Pravettoni V, and Asero R
- Subjects
- Allergens, Animals, Cross Reactions, Fishes, Humans, Immunoglobulin E, Food Hypersensitivity diagnosis, Parvalbumins
- Abstract
Background and Aims: Diagnosis of fish may represent an important challenge for the allergists. This study aimed to evaluate the diagnostic sensitivity of an in vitro multiplex assay using a comprehensive panel of fish allergens and the cross-reactivity patterns between different molecular components., Methods: 56 subjects with fish allergy were enrolled. All patients underwent specific IgE measurement using the Allergy Explorer-Alex 2™ multiplex assay (Macroarray Diagnostics, Vienna, Austria) RESULTS: The single ß-parvalbumins Clu h 1, Cyp c 1, Gad m 1, Sal s 1, Sco s 1, Thu a 1 and Xyp g 1 scored positive in 75.0%, 67.8%, 62.5%, 80.3%,80.3%, 78.8% and 73,2% patients, respectively. 14.3% scored positive for the α-parvalbumin (Raj c-parvalbumin), and 16.1% for the aldolase + enolase (Gad m 2 + 3) components. 92.8% reacted to at least one ß-parvalbumin and 96.4% to at least one of the allergens tested. Overall sensitivity was higher than that obtained using commercial extracts of cod, salmon and tuna for skin prick test (75.8%) and IgE detection (92.3%)., Conclusions: The Alex 2 showed high diagnostic sensitivity and it might be used as an additional assay to investigate the cross-reactivity patterns between different molecular components, looking for potentially safe fish species., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
40. Peanut allergy in Italy: A unique Italian perspective.
- Author
-
Asero R, Nucera E, Rizzi A, Aruanno A, Uasuf CG, Manzotti G, Villalta D, Conte M, Pastorello EA, Losappio L, Schroeder JV, Pinter E, Miglionico M, Vantaggio L, Macchia D, Radice A, Marra AM, Barzaghi C, Santucci A, Cortellini G, Peveri S, Montagni M, Demonte A, Borrelli P, Errico MA, Rivolta F, Pravettoni V, Sangalli A, Magnani M, Celi G, Yang B, Costantino MT, Deleonardi G, Boni E, Gattoni M, Rizzini FL, Di Paolo C, Montera M, Giordano A, De Carli M, Murzilli F, Fumagalli F, Maffeis L, Ghiglioni DG, Centonze S, Di Lizia M, Calafiore P, and Scala E
- Abstract
Background: Peanut allergy has not been well characterized in Italy., Objective: Our aim was to better define the clinical features of peanut allergy in Italy and to detect the peanut proteins involved in allergic reactions., Methods: A total of 22 centers participated in a prospective survey of peanut allergy over a 6-month period. Clinical histories were confirmed by in vivo and/or i n vitro diagnostic means in all cases. Potential risk factors for peanut allergy occurrence were considered. Levels of IgE to Arachis hypogea (Ara h) 1, 2, 3, 6, 8, and 9 and profilin were measured., Results: A total of 395 patients (aged 2-80 years) were enrolled. Of the participants, 35% reported local reactions, 38.2% reported systemic reactions, and 26.6% experienced anaphylaxis. The sensitization profile was dominated by Ara h 9 (77% of patients were sensitized to it), whereas 35% were sensitized to pathogenesis-related protein 10 (PR-10) and 26% were sensitized to seed storage proteins (SSPs). Sensitization to 2S albumins (Ara h 2 and Ara h 6) or lipid transfer protein (LTP) was associated with the occurrence of more severe symptoms, whereas profilin and PR-10 sensitization were associated with milder symptoms. Cosensitization to profilin reduced the risk of severe reactions in both Ara h 2- and LTP-sensitized patients. SSP sensitization prevailed in younger patients whereas LTP prevailed in older patients ( P < . 01). SSP sensitization occurred mainly in northern Italy, whereas LTP sensitization prevailed in Italy's center and south. Atopic dermatitis, frequency of peanut ingestion, peanut consumption by other family members, or use of peanut butter did not seem to be risk factors for peanut allergy onset., Conclusions: In Italy, peanut allergy is rare and dominated by LTP in the country's center and south and by SSP in the north. These 2 sensitizations seem mutually exclusive. The picture differs from that in Anglo-Saxon countries., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
41. Impact of quarantine and face masks on ragweed-induced oculorhinits during the COVID-19 pandemic in Northern Italy.
- Author
-
Dubini M, Robotti C, Benazzo M, and Rivolta F
- Subjects
- Humans, Italy epidemiology, Masks, Pandemics, Quarantine, SARS-CoV-2, Ambrosia, COVID-19
- Published
- 2022
- Full Text
- View/download PDF
42. Anaphylaxis to nimesulide.
- Author
-
Dubini M, Marraccini P, Gagliardi C, Marelli S, and Rivolta F
- Subjects
- Adult, Anaphylaxis drug therapy, Epinephrine administration & dosage, Female, Humans, Anaphylaxis chemically induced, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Sulfonamides adverse effects
- Published
- 2021
- Full Text
- View/download PDF
43. Remission of a case of multiple Hymenoptera stings-associated chronic urticaria during venom immunotherapy.
- Author
-
Dubini M, Pravettoni V, Rivolta F, Segatto G, Asero R, and Montano N
- Abstract
Hymenoptera stings mostly cause acute urticaria but we describe a case of CU after wasp stings which remitted during venom immunotherapy. IgE-mechanisms have not been fully clarified in CU, except for isolated circumstances. In our case immunotherapy has played a positive role reducing immune cells reactivity and improving urticaria symptoms., Competing Interests: The authors certify that there is no conflict interest with any financial organization regarding the material discussed in the manuscript., (© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
44. Systemic allergic reactions induced by labile plant-food allergens: Seeking potential cofactors. A multicenter study.
- Author
-
Asero R, Ariano R, Aruanno A, Barzaghi C, Borrelli P, Busa M, Celi G, Cinquini M, Cortellini G, D'Auria F, De Carli M, Di Paolo C, Garzi G, Lodi Rizzini F, Magnani M, Manzotti G, Marra A, Miceli Sopo S, Murzilli F, Nucera E, Pinter E, Pravettoni V, Rivolta F, Rizzi A, Saporiti N, Scala E, Villalta D, Yacoub MR, and Zisa G
- Subjects
- Antigens, Plant, Cross Reactions, Humans, Immunoglobulin E, Plant Proteins adverse effects, Retrospective Studies, Allergens, Food Hypersensitivity diagnosis, Food Hypersensitivity epidemiology, Food Hypersensitivity etiology
- Abstract
Background: Heat-and-pepsin-sensitive plant food allergens (PR-10 and profilin) sometimes cause systemic reaction., Objective: To detect the risk factors for systemic reactions induced by labile food allergens., Methods: A retrospective multicenter study was performed on patients with a documented history of systemic allergic reaction to labile plant food allergens and on age-matched controls with a history of oral allergy syndrome (OAS) induced by the same foods. Offending foods, their amount, and state (solid or liquid), and potential cofactors (nonsteroidal anti-inflammatory drugs, protonic pump inhibitors, exercise, alcohol, and fasting) were considered., Results: We studied 89 patients and 81 controls. Sensitization to PR-10 or profilin, IgE to Bet v 1 and/or Bet v 2, and foods causing OAS were similar in the two groups. Twenty patients experienced >1 systemic allergic reaction. Tree nuts, Rosaceae, Apiaceae, and soymilk were the main offending foods. Seventeen (19%) patients were taking a PPI when the systemic reaction occurred (vs 5% in controls; P < .025). The ingestion of the offending food in liquid form (soymilk) was frequent among patients (15%) but unusual among controls (2%; P < .025). Soy milk-induced systemic reactions were independent of PPI treatment. Fasting and excess of allergen, but not NSAID and exercise, were other relevant cofactors for systemic reactions. Systemic reactions occurred without any identifiable cofactor in 39 (44%) cases., Conclusion: PR-10- and profilin-induced systemic reactions are facilitated by PPI, ingestion of large amounts of unprocessed foods, and fasting. Soybean beverages represent a risk for PR-10 hypersensitive patients and should be avoided., (© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
45. Clusterization of patients with idiopathic pulmonary fibrosis with chemokine receptors: a possible role in the diagnostic work-up of idiopathic pulmonary fibrosis?
- Author
-
Brunetti G, Malovini A, Testoni C, Bellazzi R, Balestrino A, Meriggi A, Moscato G, Alessandrini A, Rivolta F, and Pignatti P
- Abstract
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a chronic and irreversible interstitial lung disease whose diagnosis often requires surgical lung biopsies (SLB) in cases without consistent radiological findings. We previously published that the expression of the chemokine receptors CXCR3 and CCR4 on T cells is significantly different in bronchoalveolar lavage (BAL) of IPF patients from other interstitial lung diseases. The aim of the study was to evaluate cut-off values of CXCR3 and CCR4 receptors expressed on bronchoalveolar lavage (BAL) and peripheral blood (PB) T cells useful for a differential diagnosis. Methods: Ninety-three patients were enrolled: 35 IPF, 36 interstitial lung diseases (nIPF) and 22 sarcoidosis. CXCR3 and CCR4 were evaluated on BAL and PB T lymphocytes with flow cytometry. Results: Among PB and BAL variables considered, the values of the ratio of BAL and PB CXCR3 on CD4 cells were clustered in the most informative way to obtain a classification rule for the diagnosis of patients without steroid therapy (n = 66/93). Patients with a CXCR3 ratio BAL/PB on CD4 T cells lower or equal than 1.43 were assigned to the IPF group with sensitivity = 0.87 and specificity = 0.90. All the other variables considered showed lower sensitivity and specificity in discriminating IPF patients. Conclusions: The evaluation of chemokine receptors on BAL and PB T lymphocytes could aid to discriminate IPF in subjects without steroid therapy, particularly in those patients with a high-resolution computed tomography (HRCT) non typical for Usual Interstitial Pneumonia (UIP). (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 35-43) ., (Copyright: © 2018.)
- Published
- 2018
- Full Text
- View/download PDF
46. Hypersensitivity to mugwort (Artemisia vulgaris) in patients with peach allergy is due to a common lipid transfer protein allergen and is often without clinical expression.
- Author
-
Pastorello EA, Pravettoni V, Farioli L, Rivolta F, Conti A, Ispano M, Fortunato D, Bengtsson A, and Bianchi M
- Subjects
- Adolescent, Adult, Antigens, Plant, Cross Reactions, Female, Humans, Immunoglobulin E immunology, Male, Plant Proteins, Allergens immunology, Artemisia adverse effects, Carrier Proteins immunology, Food Hypersensitivity immunology, Pollen immunology, Prunus adverse effects, Rhinitis, Allergic, Seasonal immunology
- Abstract
Background: The observation of mugwort-specific IgE antibodies in patients with peach allergy suggests that mugwort sensitization might play a role in sensitization to peach., Objective: We sought to study the clinical manifestations of mugwort hypersensitivity in patients with peach allergy, identify the common allergens, and evaluate their IgE crossreactivity., Methods: Patients with oral allergy syndrome for peach and specific IgE antibodies to mugwort were investigated for respiratory symptoms during the mugwort season. Peach and mugwort allergens were identified by means of SDS-PAGE and IgE immunoblotting. Immunoblotting inhibition experiments were done to study cross-reactivity between peach and mugwort and other pollens., Results: Seventeen patients were studied, 10 with no seasonal respiratory symptoms and 7 with clear late summer respiratory symptoms. In IgE immunoblotting the 10 asymptomatic patients reacted only to a 9-kd allergen of both mugwort and peach, whereas the 7 patients with pollinosis reacted to other allergens. Ten patients with mugwort allergy, no history of allergy to peach, and negative results for peach-specific IgE antibodies were also studied. The mugwort 9-kd protein was identified as a lipid transfer protein (LTP) homologous to peach LTP. Immunoblotting inhibition showed that IgE binding to the peach 9-kd band was totally inhibited by 4 microg of peach LTP but only by 400 microg of mugwort LTP, whereas 4 microg of both mugwort and peach LTP totally inhibited the mugwort immunoblotting. The results were similar with other pollens., Conclusions: Patients sensitized only to the 9-kd LTP of mugwort do not present hay fever symptoms, and this sensitization is a consequence of the peach sensitization.
- Published
- 2002
- Full Text
- View/download PDF
47. Evidence for a lipid transfer protein as the major allergen of apricot.
- Author
-
Pastorello EA, D'Ambrosio FP, Pravettoni V, Farioli L, Giuffrida G, Monza M, Ansaloni R, Fortunato D, Scibola E, Rivolta F, Incorvaia C, Bengtsson A, Conti A, and Ortolani C
- Subjects
- Adolescent, Adult, Allergens isolation & purification, Allergens metabolism, Amino Acid Sequence, Antigens, Plant, Carrier Proteins metabolism, Chromatography, High Pressure Liquid, Electrophoresis, Polyacrylamide Gel, Female, Food Hypersensitivity blood, Food Hypersensitivity immunology, Fruit adverse effects, Fruit chemistry, Glycosylation, Humans, Immunoblotting, Immunoglobulin E immunology, Immunoglobulin E metabolism, Isoelectric Focusing, Male, Middle Aged, Molecular Sequence Data, Plant Proteins isolation & purification, Plant Proteins metabolism, Rosales chemistry, Allergens immunology, Carrier Proteins immunology, Carrier Proteins isolation & purification, Fruit immunology, Plant Proteins immunology, Rosales immunology
- Abstract
Background: Apricots are widely grown in Europe, and allergic reactions are becoming more common, especially oral allergy syndrome. Apricot belongs to the botanical subfamily of Prunoideae, which includes peach, the major allergen of which was identified as a 9-kd protein, a lipid transfer protein (LTP)., Objective: The aim of the study was to evaluate the IgE reactivity pattern to an apricot extract in subjects with allergic reactions to apricot, as demonstrated by a positive oral challenge response., Methods: Thirty patients were investigated. All the patients displayed oral allergy syndrome (2 with systemic reactions) to apricot, with positive open food challenge responses, skin prick test responses, and serum-specific IgE antibodies to apricot. The IgE reactivity pattern to apricot extract was identified by using SDS-PAGE and immunoblotting. The major allergen, a 9-kd protein, was then purified by HPLC and characterized by periodic acid-Schiff stain, isoelectric point determination, and N-terminal amino acid sequencing., Results: The sera from all patients allergic to apricot recognized the 9-kd protein, whereas none of the other allergens, with molecular weights from 15 to 80 kd, acted as a major allergen. The 9-kd allergen has an isoelectric point of 8.7 and is not glycosylated. Determination of the N-terminal 34 amino acid sequence showed that it belongs to the LTP family, with a 94% homology with the LTP from peach. IgE blotting of the apricot extract was completely inhibited by the 9-kd purified LTP from peach., Conclusions: The major allergen of apricot is an LTP, which is highly cross-reactive with the LTP from peach.
- Published
- 2000
- Full Text
- View/download PDF
48. Identification of actinidin as the major allergen of kiwi fruit.
- Author
-
Pastorello EA, Conti A, Pravettoni V, Farioli L, Rivolta F, Ansaloni R, Ispano M, Incorvaia C, Giuffrida MG, and Ortolani C
- Subjects
- Amino Acid Sequence, Chromatography, High Pressure Liquid, Cysteine Endopeptidases chemistry, Humans, Immunoblotting, Isoelectric Focusing, Molecular Sequence Data, Molecular Weight, Allergens analysis, Cysteine Endopeptidases analysis, Fruit immunology
- Abstract
Background: Allergic reactions to fruits and vegetables are among the most frequent food allergies in adults. Kiwi fruit (Actinidia chinensis) is commonly involved, causing local mucosal, systemic, or both types of symptoms by an IgE-mediated mechanism. In a previous study on 30 patients allergic to kiwi, we identified a major allergen of 30 kd against which all sera tested clearly reacted. Other allergens were detected at 12, 24, and 28 kd., Objective: The aim of this study was to fully characterize the major kiwi fruit allergen of 30 kd., Methods: Allergens were separated and purified by high-performance liquid chromatography with anion-exchange columns. The purity of the single proteins was checked by sodium dodecylsulfate-polyacrylamide gel electrophoresis, and their allergenicity was checked by immunoblotting with a pool of sera from patients allergic to kiwi. The allergens were characterized by isoelectrofocusing and amino acid sequencing, and periodic acid-Schiff stain was used to detect glycoproteins., Results: Proteins of 30, 28, 24, and 17 kd were purified by high-performance liquid chromatography. IgE binding indicated the 30 kd protein, which showed an isoelectric point of 3.5, as the major allergen of kiwi. Determination of its partial amino acid sequence and comparison with the Swiss Protein Bank showed that this was actinidin, the main protein component of kiwi. The 24 and 28 kd proteins had the same N-terminal sequence, which did not correspond to any known protein. The 17 kd protein had a blocked N-terminal sequence., Conclusions: These results demonstrate that the major allergen of kiwi fruit, Act c 1, is actinidin, a proteolytic enzyme belonging to the class of thiol-proteases. Two other allergens of 24 and 28 kd appear identical on amino acid sequencing.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.